Core Viewpoint - The company received a regulatory letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting a detailed response concerning its small loan business and related financial disclosures [1][2]. Group 1: Small Loan Business and Debt Transfer - The company’s subsidiary, Shanghai Angli Jiuding Pawn Co., transferred a debt of 57 million yuan to its joint venture, Shanghai Xuhui Angli Small Loan Co., which has paid 40 million yuan, leaving a balance of 17 million yuan [1][2]. - The company reversed a loan impairment loss of 39.25 million yuan, significantly impacting its net profit attributable to shareholders [1][2]. - The debt transfer agreement was signed to fulfill obligations under a previous cooperation agreement, which aimed to mitigate risks associated with uncollectible loans [6][14]. Group 2: Financial Data and Impairment Losses - The company reported a total loan issuance and advance balance of 425,000 yuan at the end of 2024, with a loan loss provision of 2.0599 million yuan [16][18]. - The impairment loss for the loans to Shanghai Xuhui Angli Small Loan Co. was calculated at 1.275 million yuan, reflecting a 75% provision rate due to the company's financial difficulties [12][16]. - The company’s financial statements indicated a net profit loss of 23.14 million yuan for the year, with significant asset impairment losses recorded [16][18]. Group 3: Legal and Regulatory Compliance - The company’s audit firm confirmed that the accounting treatment for the impairment reversals and provisions complied with accounting standards [19]. - The company faced legal challenges regarding the collection of loans, which were complicated by ongoing litigation involving the borrowers [9][14]. - The Shanghai First Intermediate People's Court ruled in favor of the company in a related lawsuit, clarifying the debt relationship with the small loan company [15][16].

| 股票代码：600153 | 股票简称：建发股份 | | 公告编号：临 | 2025—034 | | --- | --- | --- | --- | --- | | 债券代码：137601 | 债券简称：22 建发 | Y4 | | | | 债券代码：115755 | 债券简称：23 建发 | Y1 | | | | 债券代码：240217 | 债券简称：23 建发 | Y2 | | | | 债券代码：240650 | 债券简称：24 建发 | Y1 | | | | 债券代码：241016 | 债券简称：24 建发 | Y2 | | | | 债券代码：241137 | 债券简称：24 建发 | Y3 | | | | 债券代码：241265 | 债券简称：24 建发 | Y4 | | | | 债券代码：241266 | 债券简称：24 建发 | Y5 | | | | 厦门建发股份有限公司 | | | | | 关于上海证券交易所对公司 2024 年年度报告 问询函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 厦门建发 ...

Core Viewpoint - Hubei Junyao Health Beverage Co., Ltd. responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about trading financial assets, other receivables, and subsidiary equity acquisitions [1] Group 1: Trading Financial Assets - Junyao Health reported a year-end balance of trading financial assets of 155 million yuan, an increase of 84.27% year-on-year, with trust financial products accounting for 134 million yuan [2] - The trust plan "Aijian Win-Win - Shanghai Huade Accounts Receivable Debt Collection Fund Trust Plan" was established on July 28, 2023, with a term of 36 months and a maximum scale of 370 million yuan, raising 305.2 million yuan, with Junyao Health subscribing 130 million yuan at an annualized benchmark interest rate of 7.1% [2] Group 2: Other Receivables - The balance of other receivables at the end of the reporting period was 124 million yuan, with a bad debt provision of 16.16 million yuan [4] - The significant other receivables primarily stemmed from a partnership with Shengjiao Winery, which ended in December 2022, where Junyao Health is owed unconsumed prepayments [4] Group 3: Supply Chain Business - Junyao Health's supply chain business recognized sales revenue of 582 million yuan in 2024, down from 809 million yuan in the previous year [6] - The company engaged in transactions with Yihe (Shanghai) Supply Chain Management Co., Ltd., with procurement and sales amounts showing a downward trend [7] Group 4: Subsidiary Equity Acquisitions - During the reporting period, Junyao Health's subsidiary Meiri Boshi acquired three e-commerce companies, with the first two being established only 20 days prior to the acquisition [8] - The acquisitions aimed to quickly enter the online market and utilize existing e-commerce store qualifications to bypass platform review cycles, with the acquisitions being zero-cost [8]

Group 1 - The company received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, specifically focusing on the disclosure of accounts payable and other receivables [1] - The accounts payable at the end of the reporting period amounted to 2.845 billion, with overdue accounts exceeding one year totaling 944 million [1] - The independent directors conducted a review and found no significant abnormalities in the long-term unsettled accounts payable and confirmed that there was no disguised inflow of funds to controlling shareholders or related parties [2] Group 2 - The other receivables at the end of the reporting period totaled 101 million, representing a year-on-year increase of 55.59%, with advances and receivables amounting to 38.16 million [2] - The independent directors assessed the situation of the top five other receivables and found the formation of these receivables to be reasonable, with no significant abnormalities detected [2]

截至2025年6月6日收盘，大东方（600327）报收于4.79元，较上周的4.79元上涨0.0%。本周，大东方6 月4日盘中最高价报4.94元。6月3日盘中最低价报4.77元。大东方当前最新总市值42.38亿元，在一般零 售板块市值排名40/59，在两市A股市值排名3387/5148。 主要内容包括长期股权投资、其他应收款与对外借款、主营业务三个方面。长期股权投资方面，公司 2024年长期股权投资余额为24.86亿元，主要投资标的企业包括无锡三凤楼商业管理有限公司、安徽陶 铝新材料研究院有限公司、无锡商业大厦集团东方汽车有限公司、上海吉道航新能源发展合伙企业、浙 江均旭房地产开发有限公司。各标的企业近三年的收入利润、资产负债、现金流状况详细列出，且说明 了相关投资与公司业务的协同关系及必要性。 对于其他应收款与对外借款，公司披露了2022年至2024年历年其他应收款前五大发生额情况，解释了对 浙江均旭延续提供借款的原因及回款风险。医疗健康业务方面，公司披露了专科特色综合医疗服务、围 绕儿童全成长发育的医疗服务、特需儿童康复三大板块的经营主体、医院或诊所明细、业务模式、主要 产品及服务、核心竞争力，并列示了各 ...

关于《盛屯矿业集团股份有限公司 专项说明 报告号：XYZH/2025CDAA4F0032 盛屯矿业集团股份有限公司 上海证券交易所上市公司管理二部： 根据贵部《关于盛屯矿业集团股份有限公司 2024 年年度报告的信息披露监管工作 函》（上证公函20250336 号）（以下简称"监管工作函"）所列的问题，本所对监管 工作函中涉及会计师的相关事项专项说明如下： 问题 1.关于毛利率上涨。年报显示，公司 2024 年实现营业收入 257.30 亿元，同 比增长 5.21%； 实现归母净利润 20.05 亿元， 同比增加 657.63%； 主营业务毛利率 19.15%， 较去年同期增加 8.21 个百分点。其中，钴产品和铜营业收入大幅增长，毛利率分别达 到 43.55%、35.23%；贸易服务及其他产品类营业收入规模逐年下降，2024 年较上年减 少 61.58%，但毛利率较以前年度出现明显增长。请公司补充披露：（1）结合公司主要 产品及原材料结构、价格走势以及同行业可比公司等情况，说明公司 2024 年毛利率维 持较高水平的合理性；（2）结合贸易类上下游价格变动、成本费用归集以及主要客户 变动情况等，说明公司此类业 ...